Breaking News

Samsung Biologics, APRINOIA Enter mAb Pact

Samsung will provide cell line development, process development, cGMP manufacturing to IND filing support, for Alzheimer's antibody candidate

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

Samsung Biologics entered into a contract development and manufacturing agreement with APRINOIA Therapeutics to develop an anti-tau monoclonal antibody candidate to treat primary and secondary tauopathies, including Progressive Supranuclear Palsy and Alzheimer’s disease, which are all currently incurable. The candidate was selected from APRINOIA’s antibody platform to target specific pathological tau aggregates with novel conformation-dependent epitopes, aiming to slow down diseas...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters